



Centrose Granted Patent Covering Proxalpha

MADISON, WI. January 26, 2024 – Centrose LLC, a biotechnology company transforming antibody drug conjugate (ADC) technology announced today that the European Patent Office has granted Centrose patent protection to its potent B-cell targeted EDC, Proxalpha.

Using its Extracellular Drug Conjugate (EDC) platform technology, Centrose developed a second generation ADC for the treatment of B-cell related diseases. Due to CD20's inability to internalize, rituximab and other CD20 targeted antibodies have not been useful for making first generation ADCs. This changed when Centrose discovered that a novel CD20 multi-protein complex located on the outer membrane of B-cells could be targeted using a type of second generation ADC.

In model studies, Proxalpha has shown typical ADC pharmacokinetic properties and a remarkable safety profile in non-human primates at levels that completely eradicate *in vivo* modeled B-cell lymphomas. Proxalpha is considered a second generation antibody drug conjugate (ADC) because it does not internalize, targets a protein not useful for first generation ADCs, and consists of a non-releasing non-cleavable linker. Yet Proxalpha consists of all three ADC parts; antibody, linker and drug and as such, manufacturing and administration are identical to first generation ADCs.

"Our goal is to partner with companies looking to add to, or start their ADC portfolios," said Dr. James Prudent, CEO of Centrose. Dr. Prudent went on to say that, "Today we are focused on moving Proxalpha into the clinic but continue to expand our knowledge of how cells communicate with their surrounding via a yet to be fully defined complex of signaling networks".

About Centrose

Centrose is a drug discovery company that is creating second generation ADCs. Its mission is to deliver on the promise of precision therapy by bringing safe and effective therapies to people with untreatable health problems. Centrose focuses on the chemistry and biology that is unique to humans.

Contact:

Centrose

918 Deming Way, Madison WI 53717

businessdevelopment@centrosepharma.com